SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061989
Filing Date
2023-11-09
Accepted
2023-11-09 16:02:29
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K spry-20231109.htm   iXBRL 8-K 65189
2 EX-99.1 spry-ex99_1.htm EX-99.1 248612
3 GRAPHIC img41264513_0.jpg GRAPHIC 32408
  Complete submission text file 0000950170-23-061989.txt   501720

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT spry-20231109_pre.xml EX-101.PRE 11556
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT spry-20231109_lab.xml EX-101.LAB 18693
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT spry-20231109.xsd EX-101.SCH 2468
8 EXTRACTED XBRL INSTANCE DOCUMENT spry-20231109_htm.xml XML 4893
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

IRS No.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 231392189
SIC: 2834 Pharmaceutical Preparations